Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

NCT01707758 | Withdrawn DMC

• 1 other identifier: 13421
• Study Type: observational
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

Conditions

Pancreatic Cancer

Keywords

pancreatic cancer; nanoparticle; proteases; cell survival; tumor progression; angiogenesis; tissue remodeling/invasion

Study Arms (1)

pancreatic cancer

This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients will be recruited from the University of Kansas Cancer Center prior to any treatment for their pancreatic cancer. Final histology and staging will be recorded and correlated with protease concnentration. Healthy subjects will be recruited from the University of Kansas and Kansas State community.

You may qualify if:

• Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis.
• Patients will have had no prior treatment or surgery
• Subjects will have no prior history of any cancer

You may not qualify if:

• Any prior treatment for pancreatic cancer
• Poorly controlled diabetes
• Poorly controlled diabetes

Sponsors & Collaborators

• University of Kansas: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Approximately 1 tablespoon of blood will be collected from each subject.

MeSH Terms

Conditions

Pancreatic Neoplasms; Disease Progression

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Stephen Williamson, MD

  University of Kansas Medical Center Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 12, 2012
• First Posted: October 16, 2012
• Study Start: October 1, 2012
• Primary Completion: February 1, 2013
• Study Completion: February 1, 2013
• Last Updated: May 16, 2013

Record last verified: 2013-05